RxDoctor Payments Data

Freshteh Salehi, MD

Internal Medicine · Troy, NYNPI 1801990155

Payments from drug & device makers

$3,053in general payments, 2019–2025

Across 169 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$986
  • AstraZeneca$891
  • Novo Nordisk$176
  • Lilly USA, LLC$174
  • Boehringer Ingelheim$172
  • Novartis$169
  • plus $487 from 12 others

What the payments were for

  • Food & beverage$3,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,053 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$73,585
Medicare patients
199
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban244$104,569
JardianceEmpagliflozin56$69,002
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$57,783
FarxigaDapagliflozin Propanediol54$56,028
TrulicityDulaglutide37$36,143
XareltoRivaroxaban29$34,809
EntrestoSacubitril/Valsartan24$23,576
JanuviaSitagliptin Phosphate14$16,844
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$13,265
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,745
ArexvyRsvpref3 Antigen/As01e/Pf36$10,729
MyrbetriqMirabegron36$10,638
Rosuvastatin Calcium362$7,399
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog54$7,290
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$6,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$63$108,281256 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arexvy$986$81,776102 claims
Boehringer IngelheimJardiance$172$69,00256 claims
AstraZenecaFarxiga, Breztri Aerosphere$891$66,77368 claims
Lilly USA, LLCTrulicity$174$36,14337 claims
Johnson & JohnsonXarelto$130$34,80929 claims
NovartisEntresto$169$23,57624 claims
Astellas Pharma US IncMyrbetriq$19$10,63836 claims
AbbVieSynthroid$64$2,60140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Troy

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →